Although this combination strategy has shown antitumor activity and survival benefits in glioblastoma [155], robust clinical data evaluating OVs combined with PD‐1/PD‐L1 inhibitors specifically in GC are currently scarce. The gene discussed is PDCD1; the disease is gastric cancer.